Coated medical devices for the treatment of vulnerable plaque
First Claim
1. An intraluminal medical device for the treatment of atherosclerotic vulnerable plaque comprising:
- a stent configured to provide structural support for a fibrous cap of a vulnerable plaque lesion;
a biocompatible vehicle affixed to at least a portion of the stent, the biocompatible vehicle including at least one layer in direct contact with the internal surface of a vessel in which the stent is positioned;
at least one first agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the inflammation associated with the acute phase of the vulnerable plaque lesion;
at least one second agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the lipid core associated with the chronic phase of the vulnerable plaque lesion, the biocompatible vehicle being configured to release the at least one first agent faster than the at least one second agent and configured to release the at least one first agent for a shorter duration than the at least one second agent;
at least one third agent in a therapeutic dosage incorporated into the biocompatible vehicle for preventing neointimal hyperplasia caused by the placement of the stent.
3 Assignments
0 Petitions
Accused Products
Abstract
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism'"'"'s reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism'"'"'s reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.
-
Citations
30 Claims
-
1. An intraluminal medical device for the treatment of atherosclerotic vulnerable plaque comprising:
-
a stent configured to provide structural support for a fibrous cap of a vulnerable plaque lesion; a biocompatible vehicle affixed to at least a portion of the stent, the biocompatible vehicle including at least one layer in direct contact with the internal surface of a vessel in which the stent is positioned; at least one first agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the inflammation associated with the acute phase of the vulnerable plaque lesion; at least one second agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the lipid core associated with the chronic phase of the vulnerable plaque lesion, the biocompatible vehicle being configured to release the at least one first agent faster than the at least one second agent and configured to release the at least one first agent for a shorter duration than the at least one second agent;
at least one third agent in a therapeutic dosage incorporated into the biocompatible vehicle for preventing neointimal hyperplasia caused by the placement of the stent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
-
Specification